Your browser doesn't support javascript.
loading
Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.
Herrero, Astrid; Toubert, Cyprien; Bedoya, Jose Ursic; Assenat, Eric; Guiu, Boris; Panaro, Fabrizio; Bardol, Thomas; Cassese, Gianluca.
Affiliation
  • Herrero A; Department of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Toubert C; Department of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Bedoya JU; Department of Hepatology and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Assenat E; Department of Digestive Oncology, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Guiu B; Department of Radiology, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Panaro F; Department of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
  • Bardol T; Laboratory of rare human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.
  • Cassese G; Division of Minimally Invasive and Robotic HPB Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
Hepatobiliary Surg Nutr ; 13(1): 71-88, 2024 Feb 01.
Article in En | MEDLINE | ID: mdl-38322198
ABSTRACT
Despite the improvements in surgical and medical therapy for hepatocellular carcinoma (HCC), recurrence still represents a major issue. Up to 70% of patients can experience HCC recurrence after liver resection (LR), as well as 20% of them even after liver transplantation (LT). The patterns of recurrence are different according to both the time and the location. Similarly, the risk factors and the management can change not only according to these patterns, but also according to the underlying liver condition and to the first treatment performed. Deep knowledge of such correlation is fundamental, since prevention and effective management of recurrence are undoubtedly the most important strategies to improve the outcomes of HCC treatment. Without adjuvant therapy, maintaining very close monitoring during the first 2 years in order to diagnose curable recurrence and continue this monitoring beyond 5 years because late recurrences exist, remains our only possibility today. Surgery represents the cornerstone treatment for HCC, including both LT and LR. However, new interesting therapeutic opportunities are coming from immunotherapy that has shown encouraging results also in the adjuvant setting. In such a complex and evolutionary scenario, the aim of this review is to summarize current strategies for the management of HCC recurrence, focusing on the different possible scenarios, as well as on future perspectives.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Hepatobiliary Surg Nutr Year: 2024 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Hepatobiliary Surg Nutr Year: 2024 Type: Article Affiliation country: France